CMP (Comprehensive Metabolic Panel) Longevity-Medicine Target Ranges

What the CMP Actually Measures

The CMP is a 14-marker blood panel ordered routinely by primary-care physicians, but its individual components contain far more prognostic information than a binary normal/abnormal read. The panel divides into four physiological clusters: glucose metabolism, kidney function, liver function, and electrolyte/fluid balance.

The Four Physiological Clusters

Glucose metabolism: Fasting glucose alone.

Kidney function: Blood urea nitrogen (BUN), serum creatinine, estimated glomerular filtration rate (eGFR), and the BUN-to-creatinine ratio.

Liver function: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin.

Electrolytes and proteins: Sodium, potassium, chloride, bicarbonate (CO2), calcium, total protein, and albumin.

Why Standard Ranges Are Not Longevity Ranges

Laboratory reference intervals are derived from population distributions, typically the central 95th percentile of a tested cohort. That cohort includes people with subclinical metabolic syndrome, early nonalcoholic fatty liver disease, and pre-diabetes. A result at the 94th percentile of a metabolically average population is still flagged "normal" even when it predicts meaningfully worse outcomes over a 20-year horizon.

The Framingham Offspring Study, which followed 3,514 participants over 8 years, showed that fasting glucose between 91 and 99 mg/dL (technically normal) was associated with a 2.33-fold higher risk of developing type 2 diabetes compared to glucose below 90 mg/dL [1]. That single finding illustrates the gap between a laboratory's "normal" flag and a longevity-medicine optimal target.

Glucose: The Most Consequential CMP Marker

Fasting glucose is the most actionable single number on the CMP for predicting long-term metabolic trajectory.

Standard vs. Optimal Targets

The American Diabetes Association classifies fasting glucose as normal below 100 mg/dL, pre-diabetic at 100 to 125 mg/dL, and diabetic at 126 mg/dL or above [2]. Longevity-medicine practice, drawing on the Framingham and ARIC cohort data, narrows the optimal window to 72 to 85 mg/dL fasting.

Above 85 mg/dL, continuous glucose monitor studies and epidemiological data suggest rising postprandial excursion risk and early insulin-secretion compensation, even while A1c remains below 5.7%. A fasting glucose of 95 mg/dL is not dangerous acutely. Over a decade, repeated postprandial stress at that baseline accelerates endothelial glycation.

Pairing Glucose with Fasting Insulin

The CMP does not include insulin. However, a fasting glucose of 84 mg/dL paired with a fasting insulin of 18 µIU/mL carries very different implications than the same glucose with an insulin of 4 µIU/mL. Ordering fasting insulin alongside the CMP allows calculation of HOMA-IR (glucose mg/dL × insulin µIU/mL ÷ 405). A HOMA-IR below 1.0 reflects high insulin sensitivity. The METSIM cohort (N=8,749 Finnish men) showed HOMA-IR above 2.0 predicted incident type 2 diabetes with a hazard ratio of 4.8 over 5.9 years [3].

Target: fasting glucose 72 to 85 mg/dL; HOMA-IR below 1.0.

Kidney Function: eGFR, Creatinine, and BUN

eGFR Interpretation in Longevity Context

EGFR is calculated from serum creatinine, age, and sex using the 2021 CKD-EPI equation endorsed by KDIGO [4]. The chronic kidney disease staging system defines stages only at eGFR below 90, treating values of 90 to 120 as uniformly "normal."

Longevity medicine treats an eGFR trajectory as more informative than a single point. An eGFR declining from 105 to 91 over three years in a 42-year-old is a signal that is invisible in standard reporting. The target is an eGFR above 90 mL/min/1.73 m² maintained through midlife, with annual trending from age 30 onward.

Creatinine and Muscle Mass Confounders

Serum creatinine is a creatine metabolism byproduct from muscle. A highly muscled individual will naturally run creatinine of 1.2 to 1.4 mg/dL without any kidney dysfunction. Using cystatin C to cross-check eGFR is advisable in athletes or anyone with serum creatinine above 1.2 mg/dL but no other kidney markers of concern [4].

BUN and the BUN/Creatinine Ratio

BUN (blood urea nitrogen) rises with high protein intake, dehydration, gastrointestinal bleeding, or impaired kidney clearance. A BUN of 22 mg/dL might reflect adequate hydration in a person eating 80 g protein per day, or early kidney stress in a sedentary person eating 50 g.

The BUN/creatinine ratio provides context. A ratio above 20:1 suggests pre-renal causes (dehydration, high protein load, reduced cardiac output). Below 10:1 may point to liver disease reducing urea synthesis or very low protein intake. Longevity target: BUN 10 to 18 mg/dL with ratio 12 to 16:1.

Liver Function: ALT, AST, ALP, and Bilirubin

Liver enzymes are the most commonly misread CMP components in standard care. The conventional upper limits of normal (ULN) were set decades ago on populations that included undiagnosed metabolic liver disease.

ALT: The Key Steatosis Marker

ALT is the most liver-specific of the panel enzymes. A 2010 analysis of NHANES data published in the American Journal of Gastroenterology proposed revised ULN values of 29 U/L for men and 22 U/L for women, derived from healthy non-obese, non-drinking, hepatitis-free participants [5].

Longevity-medicine practice tightens this further: an ALT above 25 U/L in men or 19 U/L in women, even within the lab's printed reference range, warrants investigation for early hepatic steatosis. The global prevalence of nonalcoholic fatty liver disease (NAFLD) is approximately 25%, making subclinical steatosis one of the most common sources of mildly elevated ALT in ambulatory patients [6].

An ALT persistently between 30 and 45 U/L in a male patient with a BMI of 27 and a fasting glucose of 96 mg/dL is a cluster signal for early metabolic syndrome, not a reassuring "normal."

AST/ALT Ratio

When AST exceeds ALT, the differential broadens beyond simple steatosis. An AST/ALT ratio above 2:1 raises suspicion for alcoholic hepatitis or advanced fibrosis. A ratio below 1.0 with both values mildly elevated is the typical NAFLD pattern.

ALP and Bilirubin

ALP elevation can reflect bone turnover, cholestatic liver disease, or thyroid dysfunction and should be interpreted alongside gamma-glutamyl transferase (GGT), which is not part of the standard CMP but is often added. Total bilirubin is a mild antioxidant at low-normal values. Observational data from a 2015 NHANES analysis linked bilirubin in the upper-normal range (0.8 to 1.2 mg/dL) with lower cardiovascular event rates compared to values below 0.4 mg/dL, though causality is not established [7].

Longevity targets: ALT <25 U/L (men), <19 U/L (women); AST <22 U/L; ALP 40 to 90 U/L; bilirubin 0.6 to 1.2 mg/dL.

Electrolytes: Sodium, Potassium, Chloride, and Bicarbonate

Sodium and Osmotic Regulation

The conventional sodium range of 135 to 145 mEq/L is wide. Population studies associate sodium at the high end of normal (above 142 mEq/L) with modestly accelerated aging biomarkers. A 2023 study in eBioMedicine (N=11,255, NHANES) found that serum sodium above 142 mEq/L was associated with a higher biological age score and increased risk of chronic disease over a 15-year follow-up, with an odds ratio of 1.39 for premature biological aging [8].

Longevity target: sodium 137 to 142 mEq/L, with hydration habits sufficient to keep the value below 142 mEq/L consistently.

Potassium and Cardiovascular Risk

Potassium sits at the intersection of dietary quality, kidney function, and cardiac rhythm. Low-normal potassium (3.5 to 3.8 mEq/L) is associated with higher blood pressure and ventricular ectopy even without frank hypokalemia. A dietary pattern sufficient to maintain potassium above 4.0 mEq/L typically reflects adequate fruit, vegetable, and legume intake.

The ARIC study (N=14,844) found that serum potassium below 4.0 mEq/L was independently associated with a 10 to 16% higher incidence of new atrial fibrillation over a 20-year follow-up [9].

Longevity target: potassium 4.0 to 4.5 mEq/L.

Bicarbonate (CO2) and Acid-Base Homeostasis

Serum bicarbonate on the CMP reflects the metabolic component of acid-base balance. Chronic low-grade metabolic acidosis, defined as bicarbonate persistently at 22 to 24 mEq/L (technically normal, low end), accelerates muscle catabolism and bone mineral loss. A 2015 meta-analysis in the American Journal of Kidney Diseases found that each 1 mEq/L decrease in serum bicarbonate below 26 mEq/L was associated with a 3% faster decline in eGFR in patients with CKD stages 1 to 3 [10].

Longevity target: bicarbonate 24 to 28 mEq/L; values below 23 warrant dietary acid-load review regardless of kidney status.

Albumin and Total Protein: Nutritional and Hepatic Integrity

Albumin as a Longevity Biomarker

Albumin is one of the most powerful longevity predictors in the CMP. The SENECA study on European elderly showed that albumin below 4.0 g/dL, even within the conventional normal range (3.5 to 5.0 g/dL), predicted all-cause mortality over a 10-year follow-up with a hazard ratio of 1.38 per 0.5 g/dL decrement [11]. Albumin reflects both liver synthetic function and nutritional protein status.

In clinical practice, a 55-year-old with albumin of 3.8 g/dL (flagged normal) may be experiencing early hepatic synthetic decline or protein malnutrition. Neither condition will be caught until the value falls below 3.5 g/dL by standard criteria.

The HealthRX Longevity CMP Scoring Framework stratifies each of the 14 CMP markers into three tiers: "Conventional Normal" (lab flag threshold), "Longevity Yellow Zone" (within conventional range but outside optimal), and "Longevity Green Zone" (optimal for long-term function). Albumin occupies the Yellow Zone from 3.5 to 4.2 g/dL and the Green Zone from 4.2 to 5.0 g/dL. This three-tier architecture allows physicians to generate a composite CMP Longevity Score at each visit and trend it over time rather than simply pass/fail each marker.

Total Protein

Total protein (6.3 to 8.2 g/dL conventional range) reflects both albumin and globulin fractions. An elevated total protein with low-normal albumin implies elevated globulins, which may reflect chronic inflammation, plasma cell dyscrasias, or chronic infection. Longevity target: total protein 7.0 to 7.9 g/dL with albumin/globulin ratio above 1.5.

Calcium: Often Overlooked, Rarely Optimal

Serum calcium on the CMP reflects ionized calcium, protein-bound calcium (mostly albumin-bound), and complexed calcium. The conventional range (8.5 to 10.2 mg/dL) is wide enough to miss early hyperparathyroidism, which often presents with calcium persistently in the high-normal range (9.8 to 10.1 mg/dL).

Primary hyperparathyroidism affects approximately 1 in 1,000 adults and is the most common cause of asymptomatic hypercalcemia found on routine CMP [12]. Longevity medicine flags any calcium above 9.8 mg/dL for repeat testing with concurrent PTH and 25-hydroxyvitamin D.

Longevity target: calcium 9.0 to 9.7 mg/dL. An albumin-corrected calcium calculation (add 0.8 mg/dL per 1 g/dL that albumin falls below 4.0 g/dL) is essential when albumin is below 4.0.

How to Trend CMP Results Over Time

Serial Testing Strategy

A single CMP is a photograph. Serial CMPs are a film. Annual testing from age 30, with semiannual testing during active metabolic optimization, generates the longitudinal trends that reveal early kidney function decline, progressive hepatic steatosis, and creeping insulin resistance before any single value crosses a conventional threshold.

The UKPDS (United Kingdom Prospective Diabetes Study, N=5,102) demonstrated that glycemic deterioration in type 2 diabetes follows a progressive trajectory beginning 10 to 12 years before clinical diagnosis [13]. That deterioration is detectable in serial fasting glucose data years before an A1c reaches 5.7%.

Interpreting Directional Drift

Directional drift is the pattern of a marker moving consistently toward the boundary of its optimal range across three or more annual draws. A fasting glucose trending 81, 84, 88, 93 over four years is a clear trajectory toward impaired fasting glucose, even though all four values are technically "normal." A clinical decision to intervene at 84 mg/dL is far more effective than waiting for the 100 mg/dL threshold.

The same logic applies to eGFR (declining trajectory), ALT (rising trajectory), and albumin (declining trajectory over decades).

Confounders to Document at Every Draw

Acute illness, dehydration, high-intensity exercise in the 48 hours before the draw, alcohol within 72 hours, recent dietary changes, and new medications all shift CMP values. Standardizing the draw conditions (12-hour fast, no exercise the prior evening, well-hydrated) reduces inter-visit noise and makes trending more reliable.

Medications That Alter CMP Values

Several common drugs shift CMP markers in predictable directions that can be misread as disease:

Statins: May raise ALT and AST in 1 to 3% of patients at standard doses, occasionally into the 3x ULN range that defines clinically significant hepatotoxicity [14].

Metformin: Reduces glucose and may lower B12 (not on CMP), occasionally raises creatinine slightly by competing with renal tubular secretion.

ACE inhibitors and ARBs: Raise creatinine by 10 to 15% and may raise potassium, particularly in patients with baseline eGFR below 60.

NSAIDs (chronic use): Reduce eGFR by inhibiting prostaglandin-mediated afferent arteriolar dilation. Regular ibuprofen use can drop eGFR by 5 to 10 mL/min/1.73 m² in susceptible patients.

Proton pump inhibitors (PPIs): Reduce magnesium (not on standard CMP) and, with long-term use, are associated with declining eGFR in observational data [15].

Documenting current medications at every CMP draw is as important as documenting fasting status.

CMP Longevity Targets at a Glance: Reference Table

| Marker | Conventional Normal | Longevity Optimal | |---|---|---| | Fasting glucose | 70 to 99 mg/dL | 72 to 85 mg/dL | | BUN | 7 to 20 mg/dL | 10 to 18 mg/dL | | Creatinine (men) | 0.7 to 1.3 mg/dL | 0.7 to 1.1 mg/dL | | eGFR | >60 mL/min/1.73 m² | >90 mL/min/1.73 m² | | BUN/Cr ratio | 10 to 20 | 12 to 16 | | Sodium | 135 to 145 mEq/L | 137 to 142 mEq/L | | Potassium | 3.5 to 5.0 mEq/L | 4.0 to 4.5 mEq/L | | Chloride | 98 to 106 mEq/L | 100 to 106 mEq/L | | CO2 (bicarbonate) | 22 to 29 mEq/L | 24 to 28 mEq/L | | Calcium | 8.5 to 10.2 mg/dL | 9.0 to 9.7 mg/dL | | Total protein | 6.3 to 8.2 g/dL | 7.0 to 7.9 g/dL | | Albumin | 3.5 to 5.0 g/dL | 4.2 to 5.0 g/dL | | ALT (men) | <40 U/L | <25 U/L | | ALT (women) | <32 U/L | <19 U/L | | AST | <40 U/L | <22 U/L | | ALP | 44 to 147 U/L | 40 to 90 U/L | | Total bilirubin | 0.2 to 1.2 mg/dL | 0.6 to 1.2 mg/dL |

Clinical Guidance from Professional Bodies

The American Association of Clinical Endocrinology (AACE) 2022 Comprehensive Type 2 Diabetes Management Algorithm states: "Fasting plasma glucose and A1C should be interpreted in the context of body composition, insulin resistance markers, and trends over time rather than absolute thresholds alone." [16]

The KDIGO 2024 CKD Guidelines specify: "eGFR should be trended longitudinally; a confirmed decline of more than 5 mL/min/1.73 m² per year or more than 10 mL/min/1.73 m² over 5 years constitutes rapid progression and warrants urgent evaluation regardless of absolute CKD stage." [4]

These two guideline statements together support the longevity-medicine practice of treating trajectory as a primary decision variable rather than relying exclusively on threshold crossings.